The right mix matters in biopharma leadership

Breaking the biopharma glass ceiling isn?t just a moral issue; it?s a shareholder issue. McKinsey reported in a recent study that companies in the top quartile for gender diversity are 15 percent more likely to generate financial returns above the industry average; those in the top quartile for racial and ethnic diversity are 35 percent more likely to do so.

The right mix of experience, perspectives and backgrounds is also a patient issue. Whether it?s choosing the right endpoint for a prospective therapy or marketing a product in a way that will enable physicians and patients to access the right medicine at the right time, more companies are beginning to understand the need to diversify their ranks and groom leadership teams as diverse as the clinicians and families they?re trying to reach. It?s good business and it?s good for patients.

There are biopharma compani